BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 27, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 28, 2003

View Archived Issues

ET-743 is associated with changes in the gene expression of sarcoma cells

Read More

Preliminary phase I results on EKB-569 for advanced colorectal cancer

Read More

Potential use of SB-277011-A in preventing relapse to cocaine abuse

Read More

BP-897 ameliorates dyskinesia induced by levodopa in PD

Read More

CeNeS strengthens CNS pipeline through acquisition of TheraSci

Read More

ELITE trial studies TOBI for early-onset P. aeruginosa in cystic fibrosis

Read More

New pivotal Synvisc trial to expand U.S. label

Read More

Enrollment completed in phase II Veronate study

Read More

Sinovac seeks approval to advance SARS vaccine into clinical testing

Read More

WHO collaborates with Acambis on ChimeriVax-JE development

Read More

Orphan drug status for Advanced Biotherapy antibodies targeting interferon gamma

Read More

Antisoma and EMD Lexigen create immunocytokine fusion protein

Read More

BioInvent acquires proteins for development of osteoarthritis therapeutic

Read More

Introgen and SWOG to evaluate Advexin plus surgery in phase II trial

Read More

Novel 5-HT2C ligands and their use reported by GSK researchers

Read More

Enanta presents two series of antibacterial macrolides

Read More

New thrombin receptor antagonists prepared and tested at Schering

Read More

Schering researchers describe new histamine H3 antagonists and their use

Read More

Bayer scientists design new hypoglycemic and hypolipidemic agents

Read More

Novel agents for cytomegalovirus infection discovered at Bayer

Read More

Potent analgesic activity and favorable safety profile reported for new nAChR agonist

Read More

Plenaxis receives FDA approval

Read More

Liver histology improvements in phase III study of emtricitabine for hepatitis B

Read More

P2X3 receptor antagonist INS-48506 is a potent analgesic in rodent models

Read More

Salix submits amendment to NDA for rifaximin

Read More

Schering-Plough takes option to license intranasal pleconaril rights

Read More

Atypical anxiolytic JNJ-5234801 may be effective at doses not associated with CNS side effects

Read More

Improved hemodynamic profile for new iron-containing hematinic agent ABT-870

Read More

New drug candidate activates CREB function and ameliorates long-term memory

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing